Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma
Source: MDLinx, August 2020
Researchers conducted this final analysis of a multicenter, open-label, uncontrolled phase II study to test the long-term safety and effectiveness in treatment-naive Japanese patients with advanced melanoma, including acral or mucosal subtypes, and subsequent therapy after discontinuation of the investigational agents. Study participants received four doses of nivolumab (1 mg/kg i.v.) in combination with ipilimumab (3 mg/kg i.v.) at 3-week intervals, followed by doses of nivolumab (3 mg/kg i.v.) at 2-week intervals. In Japanese patients with melanoma including acral and mucosal subtypes, which is consistent with the CheckMate 067 study, long-term survival with nivolumab plus ipilimumab has been shown.
